In this study, we developed a modified poly-di-methyl-siloxane (PDMS) system for the delivery of conjugated drugs (PG+LHRH and PTX+LHRH) for the targeted suppression of triple-negative breast cancer cells. This evidence concerns the gene GNRH1 and triple-negative breast carcinoma.